David Wilson

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised UiPath (NYSE: PATH), a leading enterprise automation and artificial intelligence (AI) software company, on its acquisition of Peak, an AI-native company based in Manchester, United Kingdom.

Cooley advised PetLab Co., a rapidly growing independent pet supplement brand headquartered in London, on its majority stake sale to BC Partners, a top international investment firm.

Cooley advised DataStax, an artificial intelligence (AI) and data solution provider, on its acquisition by IBM (NYSE: IBM), a provider of global hybrid cloud and AI solutions and consulting expertise.

Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.